Abstract: Objective: Current intrapartum fetal monitoring technology is unable to provide physicians with an objective metric of fetal well-being, leading to degraded patient outcomes and increased ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Near-infrared spectroscopy (NIRS)-monitored cerebral oxygenation using the regional cerebral saturation (rScO 2) and the cerebral fractional tissue oxygen extraction (cFTOE), derived from rScO 2 and ...

7 Royal Surrey County Hospital NHS Foundation Trust and Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK ...

Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to meet its dual primary endpoints. In ...

血气分析是指通过测定人体血液的 pH 值和溶解在血液中的气体（主要指 CO 2 、O 2 ）评估机体是否存在呼吸衰竭和酸碱平衡紊乱，是抢救危重病人和术中监护的重要指标之一。 血气分析报告的解读是临床小白们绕不过去的噩梦，也是在成为临床大神路上必须打倒 ...

Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...

Aortic stenosis is 1 of the most common heart valve diseases among adults. When symptoms develop, prognosis is poor, and current guidelines recommend prompt aortic valve replacement. Depending of the ...

2025年12月份中美欧批准上市的新药中，中国批准上市的新药数量最多，为8款；美国批准7款；欧盟批准1款新药上市。 中国批准八款新药上市 2025年12月份，我国共批准8款新药上市。根据Pharmadigger数据库，其中佐来曲替尼片、库莫西利胶囊、盐酸匹米替尼胶囊和索 ...